Affiliation:
1. Department of Immunology, University Hospital Zurich, CH-8091 Zurich, Switzerland.
2. Faculty of Medicine, University of Zurich, CH-8006 Zurich, Switzerland.
Abstract
IL-2 immunotherapy expands tumor-infiltrating DCs through a lymphoid pathway, favoring the conversion of poorly immunogenic into immunogenic tumors.
Funder
Swiss National Science Foundation
EMDO Stiftung
Olga Mayenfisch Stiftung
Swiss Cancer Research
Hochspezialisierte Medizin Schwerpunkt Immunologie
Clinical Research Priority Program of the University of Zurich
Swiss Cancer MD-PhD fellowship
Fritz Rohrer-Fonds
Young Talents in Clinical Research Fellowship by the Swiss Academy of Medical Sciences
Publisher
American Association for the Advancement of Science (AAAS)
Cited by
60 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献